1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
2
|
Shin A, Kim J and Park S: Gastric cancer
epidemiology in Korea. J Gastric Cancer. 11:135–140. 2011.
View Article : Google Scholar : PubMed/NCBI
|
3
|
Bilici A, Selcukbiricik F, Demir N, Oven
Ustaalioglu BB, Dikilitas M and Yildiz O: Modified docetaxel and
cisplatin in combination with capecitabine (DCX) as a first-line
treatment in HER2- negative advanced gastric cancer. Asian Pac J
Cancer Prev. 15:8661–8666. 2014. View Article : Google Scholar : PubMed/NCBI
|
4
|
Liu J, Qu XJ, Xu L, Zang Y, Qu JL, Hou KZ
and Liu YP: Bortezomib synergizes TRAIL-induced apoptosis in
gastric cancer cells. Dig Dis Sci. 55:3361–3368. 2010. View Article : Google Scholar : PubMed/NCBI
|
5
|
Smyth EC and Cunningham D: Targeted
therapy for gastric cancer. Current treatment options in oncology.
13:377–389. 2012. View Article : Google Scholar : PubMed/NCBI
|
6
|
Wong H and Yau T: Molecular targeted
therapies in advanced gastric cancer: does tumor histology matter?
Therap Adv Gastroenterol. 6:15–31. 2013. View Article : Google Scholar : PubMed/NCBI
|
7
|
Nadauld LD and Ford JM: Molecular
profiling of gastric cancer: toward personalized cancer medicine. J
Clin Oncol. 31:838–839. 2013. View Article : Google Scholar : PubMed/NCBI
|
8
|
Huang CM, Lin JX, Zheng CH, Li P, Xie JW,
Wang JB, Lu J and Chen QY: Clinical efficacy analysis of
laparoscopy-assisted radical gastrectomy for 1380 patients with
gastric cancer. Zhonghua Wei Chang Wai Ke Za Zhi. 15:1265–1268.
2012.(In Chinese). PubMed/NCBI
|
9
|
Yoshimura F, Inaba K, Kawamura Y, Ishida
Y, Taniguchi K, Isogaki J, Satoh S, Kanaya S, Sakurai Y and Uyama
I: Clinical outcome and clinicopathological characteristics of
recurrence after laparoscopic gastrectomy for advanced gastric
cancer. Digestion. 83:184–190. 2011. View Article : Google Scholar : PubMed/NCBI
|
10
|
Wang DR, Zhao JG, Yu HF, Wang LH, Jiang
GQ, Li YK and Chen J: Laparoscopic versus open surgery for D2
gastrectomy in advanced gastric cancer. Zhonghua Wei Chang Wai Ke
Za Zhi. 15:964–966. 2012.(In Chinese). PubMed/NCBI
|
11
|
Huang Z, Li G, Xu Y, Wang G and You S:
Comparison of laparoscope-assisted D2 radical total gastrectomy and
open gastrectomy for gastric cancer. Zhonghua Wei Chang Wai Ke Za
Zhi. 17:781–784. 2014.(In Chinese). PubMed/NCBI
|
12
|
Gong J, Cao Y, Wang Y, Zhang G, Wang P and
Luo G: Three-step hand-assisted laparoscopic d2 radical gastrectomy
for Chinese obese patients: A highly efficient and feasible
surgical approach. J Cancer. 6:120–127. 2015. View Article : Google Scholar : PubMed/NCBI
|
13
|
Wang Y, Liu R, Zhang Z, Xue Q, Yan J, Yu
J, Liu H, Zhao L, Mou T, Deng H, et al: A safety study of
transumbilical single incision versus conventional laparoscopic
surgery for colorectal cancer: study protocol for a randomized
controlled trial. Trials. 16:5392015. View Article : Google Scholar : PubMed/NCBI
|
14
|
Cui M, Gong C, Jiang B, Yao Z, Chen L, Di
J, Xing J, Yang H, Zhang C, Zhang N, et al: Evaluation of immune
responses of gastric cancer patients treated by laparoscopic and
open gastrectomy. Med Oncol. 32:2532015. View Article : Google Scholar : PubMed/NCBI
|
15
|
Hu Y, Zhao G and Zheng H: Therapeutic
effects of laparotomy and laparoscopic surgery on patients with
gastric cancer. Pak J Med Sci. 31:572–575. 2015.PubMed/NCBI
|
16
|
Zhao HQ, Liu HR, Xiao L, Zheng F and Li
WM: Laparoscopic cholecystectomy in elderly patients: an evaluation
of immunity. Aging Clin Exp Res. 27:927–933. 2015. View Article : Google Scholar : PubMed/NCBI
|
17
|
Chang TC, Chen CC, Wang MY, Yang CY and
Lin MT: Gasless laparoscopy-assisted distal gastrectomy for early
gastric cancer: analysis of initial results. J Laparoendosc Adv
Surg Tech A. 21:215–220. 2011. View Article : Google Scholar : PubMed/NCBI
|
18
|
Louis-Dit-Sully C, Blumenthal B,
Duchniewicz M, Beck-Garcia K, Fiala GJ, Beck-García E, Mukenhirn M,
Minguet S and Schamel WW: Activation of the TCR complex by
peptide-MHC and superantigens. EXS. 104:9–23. 2014.PubMed/NCBI
|
19
|
Larsen SK: Cellular immune responses
towards regulatory cells. Dan Med J. 63:pii: B5188. 2016.
|
20
|
Brentville VA, Metheringham RL, Gunn B,
Symonds P, Daniels I, Gijon M, Cook K, Xue W and Durrant LG:
Citrullinated vimentin presented on MHC-II in tumor cells is a
target for CD4 T cell-mediated antitumor immunity. Cancer Res.
76:548–560. 2016. View Article : Google Scholar : PubMed/NCBI
|
21
|
Jackutė J, Žemaitis M, Pranys D,
Šitkauskienė B, Miliauskas S, Bajoriūnas V and Sakalauskas R:
Distribution of CD4(+) and CD8(+) T cells in tumor islets and
stroma from patients with non-small cell lung cancer in association
with COPD and smoking. Medicina (Kaunas). 51:263–271. 2015.
View Article : Google Scholar : PubMed/NCBI
|
22
|
Jackute J, Zemaitis M, Pranys D,
Sitkauskiene B, Miliauskas S, Bajoriunas V, Lavinskiene S and
Sakalauskas R: The prognostic influence of tumor infiltrating
Foxp3(+)CD4(+), CD4(+) and CD8(+) T cells in resected non-small
cell lung cancer. J Inflamm (Lond). 12:632015. View Article : Google Scholar : PubMed/NCBI
|
23
|
Chen M, Mohtize M, Matteï MF, Villemot JP,
Kohler C, Faure GC, Béné MC and de Carvalho Bittencourt M: Reduced
levels of both circulating CD4+ CD25+
CD127(low/neg) and CD4+ CD8(neg) invariant natural
killer regulatory T cells in stable heart transplant recipients.
Clin Exp Immunol. 163:104–112. 2011. View Article : Google Scholar : PubMed/NCBI
|